CATALYSTInvesting.com • 15h ago
HeartBeam stock soars on FDA breakthrough designationInvesting.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
Why BEAT Stock surged +2.06% Today — RQD Quant Desk Flash
$0.55 +2.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.55
Heartbeam Inc. (BEAT) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $31.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BEAT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BEAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Heartbeam Inc. (NASDAQ: BEAT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.55 (+2.06% 1D, market cap $31.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BEAT ranks #484 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BEAT compare to DRIO and NEPH in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), BEAT carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DRIO (DarioHealth Corp.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $29.4M) and NEPH (Nephros Inc.) posts a C- grade (59/100 RQD, P/E 29.8x, ROIC 18.9%, cap $34.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BEAT?
▼
Per BEAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779372), Heartbeam Inc. generated $0 in revenue, -$21.0M in net income, and -$14.6M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.55 (+0.18%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-7.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BEAT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY BEAT SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.40+2.5% Next Q
34
Q2 (-2Q)Grade E$0.41-2.4% Next Q
37
Q3 (-1Q)Grade E$0.40+37.5% Next Q
39
CurrentGrade D-$0.55-7% Hist 90D α
42
Trajectory: E (34) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BEAT Turnaround Squeeze
While BEAT currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.45) and Max Pain ($0.58) forces dealer call-delta covering toward $4.20.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BEAT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BEAT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BEAT Stock surged +2.06% Today — RQD Quant Desk Flash
Heartbeam Inc. (BEAT) surged +2.06% to $0.55, trading at 5% of its 52-week range ($0.35 – $4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($0.35 – $4) with RSI-14 at 62.8 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.55 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BEAT Headlines & Catalysts
CATALYSTStocktwits • 18h ago
HeartBeam Inc (BEAT) Profile, Company FAQs & Facts, Industry, Sector, Employee StrengthStocktwits report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREChartMill • 21h ago
Monday's session: gap up and gap down stocksChartMill report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack AssessmentYahoo Finance report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
CATALYSTwww.marketscreener.com • 1d ago
3 Stocks BEAT, MOBX, PRSO Now: FDA Breakthrough, Rare Earths and Military Drones Drive Catalystswww.marketscreener.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
FDA grants HeartBeam technology a breakthrough designation for assessing suspected heart attacks outside hospitals.Stock Titan report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
Why is Heartbeam stock surging today?Investing.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
Heartbeam stock rating held at Neutral by H.C. Wainwright on FDA newsInvesting.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 17h ago
HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECGSANTA CLARA, Calif., November 02, 2026--HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to be as Accurate as Standard 12-Lead ECG
MARKET WIREChartMill • 5d ago
Top US Stock Movers in Today's SessionToday's US session featured double-digit moves, with KPTI up 59.38% and JDZG down 77.87% among the largest percentage swings.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BEAT)
- ✓Walkthrough of BEAT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BEAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.52%📐 HORIZONTAL RANGE
2026-11-03O $0.54H $0.55L $0.54C $0.55VOL 1.70M
RES: $0.95SUP: $0.27SMA50: $0.45SMA200: $0.85
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BEAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BEAT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BEAT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BEAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BEAT)
Health Care Rank #484 of 1016
⚔️ DRIO vs BEAT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BEAT vs. DRIO, NEPH, TELA, PLRZ)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Heartbeam Inc. (BEAT) ranks #484 by composite RQD confidence (42/100, grade D-) and #793 by equity capitalization ($31.0M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with BEAT at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BEAT
ACTIVE
Heartbeam Inc. | D- | 42/100 | — | — | -35.0% | +2.06% | $31.0M | Benchmark Subject |
| DRIO DarioHealth Corp. | E | 34/100 | — | 56.6% | -35.0% | -9.37% | $29.4M | /drio-vs-beat → |
| NEPH Nephros Inc. | C- | 59/100 | 29.8x | 61.9% | 18.9% | -3.06% | $34.5M | /neph-vs-beat → |
| TELA TELA Bio Inc. | D- | 39/100 | — | 67.7% | -35.0% | -11.95% | $36.6M | /tela-vs-beat → |
| PLRZ Polyrizon Ltd. | E | 30/100 | — | — | -25.1% | +19.40% | $26.1M | /plrz-vs-beat → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001779372In its most recent audited fiscal period (FY2025, filed 2025-12-31), Heartbeam Inc. (BEAT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$21.0M, operating cash flow of -$14.0M, and free cash flow of -$14.6M (+0.6% YoY). On the balance sheet, BEAT closed FY2025 with $5.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$21.0M | -$14.0M | -$14.6M | $5.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$19.4M | -$14.5M | -$14.7M | $3.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$14.6M | -$12.1M | -$12.1M | — | — |
3. BEAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BEAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Heartbeam Inc. (NASDAQ: BEAT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.55 (+2.06% 1D, market cap $31.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BEAT ranks #484 in composite RQD confidence.
How does BEAT compare to DRIO and NEPH in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), BEAT carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DRIO (DarioHealth Corp.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $29.4M) and NEPH (Nephros Inc.) posts a C- grade (59/100 RQD, P/E 29.8x, ROIC 18.9%, cap $34.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BEAT?
Per BEAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779372), Heartbeam Inc. generated $0 in revenue, -$21.0M in net income, and -$14.6M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BEAT trading relative to its 50-day, 200-day, and 52-week technical levels?
BEAT last traded at $0.55 (+2.06% on volume of 1,696,184 shares), positioning the stock +22.22% above its 50-day simple moving average ($0.45) and -35.29% below its 200-day simple moving average ($0.85). Across its 52-week range of $0.35 to $4.00, BEAT sits at the 5.5% percentile with a 14-day RSI of 62.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.00 to $0.62).
BEAT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BEAT stock moving today?
Why BEAT Stock surged +2.06% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 42/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
BEAT — Heartbeam Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:48:45Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, BEAT scores 42 out of 100 with a letter grade of D- and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the fundamental cash engine scores 7 of 20 (ROIC -35%; FCF yield 0%), indicating the weakest pillar on operating economics. Whale/13F flow scores 11 of 20 (institutional accumulation and options positioning), the strongest pillar, which is the main upside-driver signal in the rating. Insider conviction scores 5 of 20 (SEC Form 4 and Congressional PTR cluster flow), reflecting limited insider-side support. Macro regime fit scores 9 of 20 (beta 1.0; sector sensitivity). Forensic balance sheet scores 10 of 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), reflecting a balance sheet the rating characterizes as vulnerable.
For a prospective investor evaluating the stock today, the rating implies that the investment case rests on forward catalysts and institutional interest rather than current cash generation, since the reported fundamentals show negative ROIC and zero FCF yield. Valuation tradeoffs are difficult to quantify because P/E and EV/EBITDA are not available in source data, and the company reports no revenue in the financial periods provided. The $0.54 price and $30.4M market capitalization sit against a 52-week range of $0.35 to $4, a wide band that signals high price volatility relative to the stated beta of 1.0.
Business
Heartbeam Inc. (BEAT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. Per the profile, the company's market capitalization is $0.0B in that section, while the market data section reports $30.4M. Customer base, product line, and revenue model are not available in source data. The financials show revenue of $0.0M in each reported period, so the source data does not establish how the company makes money.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-21.1M | $-21.0M | N/A | $-14.6M | $4.4M | N/A |
| FY 2024 | $0.0M | $-19.9M | $-19.4M | N/A | $-14.7M | $2.4M | N/A |
| FY 2023 | $0.0M | $-15.3M | $-14.6M | N/A | $-12.1M | N/A | N/A |
Per the SEC financials, the company reported operating losses and net losses across all three periods, with margins at 0% for gross, operating, and net per the market data. Per the market data, ROIC is -35%, and the Roarable RQD rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. Cash increased from $2.4M in FY 2024 to $4.4M in FY 2025 while free cash flow remained negative, and debt is not available in source data for any period.
Recent Catalysts & News Wire Analysis
Per the recent news section, the most prominent item is a headline stating HeartBeam stock soared on an FDA breakthrough designation, flagged as a green catalyst. Multiple sources report the same FDA Breakthrough Device Designation for heart attack assessment, with one describing the technology as aimed at assessing suspected heart attacks outside hospitals. Other items include a profile piece, a gap-up/gap-down session note, and a multi-stock catalyst roundup that names BEAT alongside MOBX and PRSO. The flagged risk watch items are limited to the yellow market-wire classifications on several entries, which the source does not further explain. Per the butterfly supply-chain graph, no proprietary signals or supply-chain links are recorded.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations beyond the Health Care and Medical/Dental Instruments classification are not available in source data. A prospective investor should note that the absence of recorded links means second-order ripples cannot be mapped from the provided data; any regulatory or commercial effects of the FDA designation on partners or customers are not available in source data.
Open Questions
- What revenue, if any, does the company generate, given that every reported period shows $0.0M?
- What is the company's debt position, since debt is reported as N/A in every period?
- What are the commercial timelines and clinical milestones following the FDA Breakthrough Device Designation?
- Why does the market capitalization differ between the profile ($0.0B) and market data ($30.4M) sections?
- What is the current cash runway, given the reported FY 2025 cash of $4.4M against FCF of $-14.6M?
BEAT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Heartbeam Inc. (BEAT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Investing.com • 15h ago
HeartBeam stock soars on FDA breakthrough designation Investing.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stocktwits • 18h ago
HeartBeam Inc (BEAT) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength Stocktwits report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 21h ago
Monday's session: gap up and gap down stocks ChartMill report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment Yahoo Finance report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST www.marketscreener.com • 1d ago
3 Stocks BEAT, MOBX, PRSO Now: FDA Breakthrough, Rare Earths and Military Drones Drive Catalysts www.marketscreener.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
FDA grants HeartBeam technology a breakthrough designation for assessing suspected heart attacks outside hospitals. Stock Titan report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Why is Heartbeam stock surging today? Investing.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Heartbeam stock rating held at Neutral by H.C. Wainwright on FDA news Investing.com report covering Heartbeam Inc. (BEAT) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BEAT Bull vs. Bear Conversation Board — What's Your Call at $0.55?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BEAT 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $0.48 (-11.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is BEAT (D- • RQD 42/100) a Buy at $0.54?
Welcome to the BEAT (Heartbeam Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.43 (-20.4%)
Spot @ $0.54 Pump the brakes on BEAT — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on BEAT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Heartbeam Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $0.64 (+18.5%)
Spot @ $0.54 BEAT cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on BEAT, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $0.54 (52-wk range $0.35 - $4.00), any beat on forward guidance forces shorts and underweight funds to chase.